Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.66 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.66 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.63 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222408 | 0.89 | ITGB3 (0.73) | NR4A1NR4A2NR4A3NPC1RAB9A | |
| SCHEMBL7296744 | 0.88 | SPHK2 (0.80) | NR4A1NR4A2NR4A3NPC1RAB9A | |
| SCHEMBL5637555 | 0.86 | NR4A1 (0.56) | NR4A1NR4A2NR4A3NPC1RAB9A | |
| SCHEMBL834204 | 0.85 | SMN1; SMN2 (0.61) | NR4A1NR4A2NR4A3NPC1RAB9A | |
| SCHEMBL6716502 | 0.85 | MEN1 (0.79) | NR4A1NR4A2NR4A3NPC1RAB9A | |
| SCHEMBL863916 | 0.84 | ALDH1A1 (0.88) | NR4A1NR4A2NR4A3NPC1RAB9A | |
| SCHEMBL748869 | 0.84 | SPHK2 (0.81) | NR4A1NR4A2NR4A3NPC1RAB9A | |
| SCHEMBL10289219 | 0.84 | HDAC3 (0.78) | NR4A1NR4A2NR4A3NPC1RAB9A | |
| SCHEMBL7287723 | 0.84 | NPC1 (0.67) | NR4A1NR4A2NR4A3NPC1RAB9A | |
| SCHEMBL5971699 | 0.83 | NR4A1 (0.68) | NR4A1NR4A2NR4A3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559455-B2 | Compound as a UBR box domain ligand | AUTOTAC INC. (KR) | 2026-02-24 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| WO-2023074936-A1 | BIFUNCTIONAL COMPOUND USING UBR BOX DOMAIN-BINDING LIGAND | 주식회사 오토텍바이오 | 2023-05-04 | — | — | WO | disclosed |
| EP-4144722-A1 | COMPOUND AS UBR BOX DOMAIN LIGAND | Autotac Inc. (KR) | 2023-03-08 | — | — | EP | disclosed |
| CN-115715285-A | Compounds as UBR box domain ligands | 奧土择破利悟 | 2023-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | NR4A1 551/4885NR4A2 274/4885NR4A3 305/4885 |
| US-12559455-B2 | Compound as a UBR box domain ligand | UBR4, UBTF, UBQLN1 | NR4A1 161/4885NR4A2 80/4885NR4A3 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.